August 2009:
Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug.
See press release for details
March 2009:
Morria' allergic rhinitis drug, MRX-4, chosen by the journal R&D Directions, as one of the "100 great Investigational Drugs" (March 2009 issue, page 28).
November 2008:
Opinion piece by Yuval Cohen featured in GEN
See GEN for details
November 2008:
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
See press release for details
October 2008:
Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
See press release for details
October 2008:
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
See press release for details
June 2008:
Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
See press release for details
June 2008:
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
See press release for details
January 2008:
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results from its Phase I Clinical Study of MRX-4 in Allergic Rhinitis patients
See press release for details
October 2007:
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
See press release for details
Septermber 2007:
Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
See press release for details
Septermber 2007:
Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary
Mazanet as Interim Chief Executive Officer
See press release for details
May 2007:
Morria Biopharmaceuticals Plc announces the close of a private placement financing round in the amount of £1.6 million.
See press release for details
May 2007:
Morria Biopharmaceuticals Plc to present at the Acumen BioFin 4th Annual Global Healthcare Conference.
See press release for details
March 2007:
Morria Biopharmaceuticals Plc to present at the Atlas Venture Japan Biopharma Partnering Conference 2007 in Tokyo on March 20th.
See press release for details
February 2007:
Morria Biopharmaceuticals Plc. Announces publication of the results of its human Pilot Study in Contact Dermatitis Patients of MRX1, a novel first-in-class MFAID .
See press release for details
November 2006:
Morria's team attends JAFCO's Japan Biotech Summit.
See press release for details
September 2006:
Review by Saul Yedgar and Yuval Cohen to be published in a special issue of Biophysica Biochemica Acta (BBA) on PLA2
June 2006:
Morria invited to attend the 2006 Jafco Biotech Conferance in Japan in November. Morria is the first European company invited since 2003 to attend this prestigious event.
May2006:
IBD animal proof-of-concept demonstrated on two of Morria's MFAIDs.
See press release for details
May 2006:
Morria participates in IBCC's AIM delegation in London.
April 2006:
Morria team interviewed by Wall Street Reporter.
April 2006:
Review on anti-inflammatory PLA2 strategy to be published in special edition of the peer-reviewed journal BBA.
Feb 2006:
Article by Yuval Cohen is published in the February issue of the BioMed Journal entitled " Anti-inflammatory drugs: are we looking for answers in the right places"?
CLICK HERE TO VIEW ALL PRESS RELEASES